N4 Pharma Plc

At N4 Pharma, we extend a warm welcome to our shareholder community, investors, and those wanting to keep up to date with all things N4 Pharma.

Established in 2014 and proudly listed on the AIM stock market in May 2017, we are a pre-clinical stage specialist pharmaceutical company committed to transforming drug delivery through our breakthrough silica nanoparticle technology, Nuvec®.

Nuvec® has a patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in gene therapy, cancer therapeutics and vaccines.

Designed to overcome some of the drawbacks of existing delivery systems. Nuvec® is safe and well tolerated even at high doses and can be delivered intravenously, sub cutaneously or intra muscular.

Watch our video animation to see Nuvec® in action.

If you'd like to know more, please post a question on our investor hub.